secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enovis CORP (ENOV)
CIK:        0001420800
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001420800-24-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enovis Q2 sales up 23% to $525M; raises adjusted EPS guidance to $2.62-$2.77
----------------------------------------------------------------------------

- Q2 net sales $525M (+23% reported, +5% comparable); Recon sales +60% reported.
- Reported net loss from cont ops $0.34/sh; adjusted EPS $0.62; adj EBITDA $90M (17.2% of sales, +190bps).
- Raised FY2024 adj EPS guidance to $2.62-$2.77 (from $2.52-$2.67); revenue narrowed to $2.08-$2.13B.
- Received FDA 510k clearance for Arvis 2.0 Shoulder and Altivate Reverse Glenoid; launches expected Q3 2024.
- Opened new manufacturing facility in San Daniele and Business Technology Center in Lisbon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420800/000142080024000019/0001420800-24-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420800/000142080024000019/cfx-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001420800-24-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer